Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.

Trial Profile

A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Tildrakizumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sun Pharma Global FZE
  • Most Recent Events

    • 24 Sep 2018 Planned End Date changed from 30 Aug 2022 to 30 Aug 2023.
    • 24 Sep 2018 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.
    • 20 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top